ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

SYNH Syneos Health Inc

42.98
0.00 (0.00%)
24 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Syneos Health Inc NASDAQ:SYNH NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 42.98 42.96 42.99 0 01:00:00

Syneos Health Schedules Second Quarter 2020 Earnings Call for Thursday, August 6, 2020

01/07/2020 8:37pm

GlobeNewswire Inc.


Syneos Health (NASDAQ:SYNH)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more Syneos Health Charts.

Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its second quarter 2020 financial results on Thursday, August 6, 2020, prior to its earnings call at 8:00 a.m. ET. 

Participants may access the conference call live via webcast on the Investor Relations section of the Syneos Health website at investor.syneoshealth.com. To participate via telephone, please dial +1 877 930 8058 within the United States or +1 253 336 7551 outside the United States, approximately 15 minutes prior to the scheduled start time. The conference ID for the call is 5227209.

A webcast replay will be available on the Investor Relations section of the Syneos Health website at investor.syneoshealth.com after 1:00 p.m. on August 6. In addition, an audio replay will be available for one week following the call and will be accessible by dialing +1 855 859 2056 within the United States or +1 404 537 3406 outside the United States. The replay ID is 5227209.

About Syneos HealthSyneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. We bring together approximately 24,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast.

Investor Relations Contact: Ronnie Speight Senior Vice President, Investor Relations+1 919 745 2745 investor.relations@syneoshealth.comPress/Media Contact: Danielle DeForgeExecutive Director, External Communications+1 781 425 2624danielle.deforge@syneoshealth.com 

1 Year Syneos Health Chart

1 Year Syneos Health Chart

1 Month Syneos Health Chart

1 Month Syneos Health Chart

Your Recent History

Delayed Upgrade Clock